Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TA-NIC plus nicotine replacement therapy to maintain smoking cessation
2005-000922-22Phase 2Unknown
- Sponsor
- Xenova Ltd.
- Start
- May 2005
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in nicotine dependence comparing TA-NIC + NRT with Placebo + NRT (2 arms). Primary endpoint: Prevention of smoking relapse at 26 weeks. Status: unknown.
02
Drugs
TA-NIC
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on 2005-000922-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000922-22.